

Accelerated elastin degradation by age-disease interaction: a common feature in age-related diseases

Jeffrey Huang

`jt.jhuang@dundee.ac.uk`

University of Dundee

Naomi Shek

University of Dundee <https://orcid.org/0009-0003-6532-855X>

Anna-Maria Choy

University of Dundee

Chim Lang

University of Dundee

Bruce Miller

COPD Foundation

Ruth Tal-Singer

Global Allergy and Airways Patient Platform

Charlotte Bolton

University of Nottingham

Neil Thomson

University of Glasgow

David Newby

British Heart Foundation/University of Edinburgh Centre for Cardiovascular Science

James Chalmers

University of Dundee

Faisal Khan

University of Dundee

Matthew Brown

University of Leicester

Brief Communication

Keywords: accelerated aging, cardiovascular diseases, desmosine, elastin degradation, COPD, abdominal aortic aneurysm, rheumatoid arthritis

Posted Date: October 13th, 2023

DOI: <https://doi.org/10.21203/rs.3.rs-3379154/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: There is a conflict of interest Please see the competing interest form attached.

Version of Record: A version of this preprint was published at npj Aging on February 27th, 2024. See the published version at <https://doi.org/10.1038/s41514-024-00143-7>.

Abstract

Aging is a major driving force for many diseases but the relationship between age, aging processes and age-related diseases is not fully understood. Fragmentation and loss of ultra-long-lived elastin are key features in aging and several age-related diseases leading to increased mortality. By comparing the relationship between age and elastin turnover with healthy volunteers, we show that accelerated elastin turnover by age-disease interaction is a common feature of age-related diseases.

Main text

Advanced age exponentially increases the risk of developing cardiovascular disease, chronic respiratory diseases including COPD and bronchiectasis, and degenerative diseases such as arthritis.(1) Around 100,000 people worldwide die each day due to age-related diseases.(2) Loss of tissue and structural integrity leading to the loss physiological integrity with age, resulting in a progressive decline of homeostasis and reduced capacity to respond to environmental stimuli, is believed to contribute to an incremental risk and severity of these diseases.(3) Several intertwined biological mechanisms including shortened telomeres, epigenetics, inflammation, macromolecular damage, altered metabolism and proteostasis, and reduced stem cells and regeneration have been proposed as key mechanisms driving the loss of physiological integrity in aging and its associated diseases(4). Although most studies have focused on the associations between these processes and chronological age or diseases, less attention has been drawn to their interactions, e.g., whether diseases and age could interact in accelerating aging processes.

Ultra-long lived proteins such as elastin, collagen, and eye lens crystalline have been considered as the Achilles heel of the aging proteome(5) as their damages and losses are not easily repaired. Among them, elastin is unique in providing the characteristics of elasticity, resilience, and deformability of tissues such as the aorta, lung, and skin etc, and its fragmentation and degradation represents an important feature of normal aging.(6) Elastin is a crosslinked polymeric network of tropoelastin monomers catalyzed by lysine oxidase during development. In adult tissues, elastin has an extremely low turnover rate with a half-life of ~ 74 years under normal conditions(7) in contrast to minutes to days for most intracellular proteins(8). In general, adult tissues lack the capability of regenerating functional elastic fibre.(9) These two unique properties imply that an increased turnover of this ultra-long-lived protein in adult tissues could result in irreversible changes to elastin-rich tissues (5). Elastin breakdown products themselves are also known to possess biological activities such as chemotactism, angiogenesis, and inflammatory responses.(10) Monitoring the activity of elastin degradation therefore could be highly relevant to better understanding aging and aging-related diseases.

We have previously investigated the activity of elastin degradation in several age-associated diseases by evaluating the concentrations of circulating total desmosine and isodesmosine (termed cDES), two crosslinking molecules unique to functional elastin(11–14). We found that cDES concentrations were positively associated with chronological age in patients with COPD(15), bronchiectasis(12, 14),

abdominal aortic aneurysm (AAA)(13), acute myocardial infarction(16), and in control participants with normal lung function and free of significant diseases.(15) The elevated cDES concentrations were significantly correlated with higher mortality and cardiovascular morbidity or mortality in these conditions.(11–15). Interestingly, the activity of elastin degradation was accelerated by an age-disease interaction in COPD(11), supporting the concept that COPD is a disease of accelerated aging. However, whether a similar age-disease interaction also drives elastin degradation in other age-related diseases is unknown. We set out to investigate whether the age-associated elastin degradation is enhanced in AAA, bronchiectasis, rheumatoid arthritis (RA) and COPD compared to control subjects.

We performed a pooled analysis of data from multiple cohorts comprising individuals with COPD (n = 1332), AAA (n = 507), bronchiectasis (n = 433) or RA (n = 111), and a control group (n = 641). Ethic approvals and informed consent have been obtained. The COPD group was combined from three observational cohorts (the ECLIPSE(17)(ClinicalTrials.gov Identifier: NCT00292552), Nottingham(17), and Scotland cohorts(18)) where individuals with GOLD stage II–IV COPD were recruited. The AAA group included two cohorts (the MA3RS(19)(ClinicalTrials.gov Identifier: NCT02229006) and UKAGS cohorts(13)) where the mean AAA size was 48 mm (standard deviation = 8 mm). The bronchiectasis patients were from the TAYBRIDGE cohort and had a median (IQR) Bronchiectasis Severity Index score of 6(4–10).(14) RA patients meeting the 1987 American College of Rheumatology (ACR) classification criteria for RA (DAS28 score = 4.6 (1.6)) were recruited in Ninewells Hospital, Dundee. With the exception of RA and control subjects, previous history of CV disease, uncontrolled hypertension or hypercholesterolemia and any other inflammatory conditions were not excluded in disease groups. The demographic details of each study group are shown in **Supplementary Table S1**. The AAA group had a higher percentage of male participants whereas the bronchiectasis and RA groups had higher percentages of females, reflecting the sex differences in the prevalence of those diseases and the fact that only men are screened for AAA in the UKAGS cohort.(20, 21). As expected, the COPD and AAA groups have higher percentages of current and ex-smokers. Our previous studies have shown that sex and smoking history did not affect cDES concentrations in adults(12, 15). Similar to the positive associations to age observed in the COPD and control populations(11), cDES concentrations correlated with age in AAA, bronchiectasis, and RA ($r = 0.43–0.48$, $p < 0.001$, **figure A-E, Supplementary Table S2**). cDES concentrations were measured using the same validated isotope dilution LC-MS/MS method(22) in the same laboratory.

To investigate the effect of age-disease interaction on elastin turnover, we compared the slopes of the regression lines between the four disease groups and the control population using a linear mixed-effects model incorporating subject-specific random effects and taking into account the effects of multiple visits from some individuals (i.e. in the ECLIPSE, Scotland, and MA3RS cohorts). We found that the slope of age to elastin turnover regression in bronchiectasis was greater compared to healthy control subjects (6.27 vs 4.45 ng L^{-1} per year, $p = 0.02$, **Figure F**). A similar effect of age-disease interaction was found in RA (5.75 vs 3.46 ng L^{-1} per year, $p = 0.003$, **figure G**). In the AAA group the predicted regression slopes is ~ 5 times greater (16 ng L^{-1} per year) when compared to the control population (3.12 ng L^{-1} per year; $p <$

0.001; **figure H**). The difference remained if those less than 60 years old (defined by the lower limit of 95% interval of the AAA group) in the control group were excluded ($p = 0.007$ for the interaction). Together with the previous observation in COPD (11), these results strongly suggest that RA, AAA, bronchiectasis, and COPD are diseases of accelerated aging, and that the acceleration is dependent on an age-disease interaction where the differences between the disease groups and control becomes greater as age increases.

Increased cDES concentrations have implications for mortality in COPD(15), bronchiectasis(14), and AAA(13). Notably, the association between cDES concentrations and cardiovascular diseases was particularly strong among these diseases, probably explained by the abundant expression of elastin in the vascular system. Indeed, a significant interaction (greater slope) was also observed in COPD patients with cardiovascular diseases compared to COPD participants without this comorbidity in the ECLIPSE cohort (8.69 ng vs 5.48 ng L⁻¹ per year, $p < 0.037$, **Figure I**). The notion is also supported by the fact that AAA showed the greatest slope among the four diseases studied. Furthermore, cDES concentrations were significantly associated with pulse wave velocity (a measure of arterial stiffness) in patients with COPD(15) or acute myocardial infarction(16) further strengthening its clinical relevance to the cardiovascular system with elastin breakdown mirroring arterial stiffness. These data may provide a potential explanation as to why cardiovascular morbidities and mortality are higher in COPD, RA, and bronchiectasis.

It is unclear how this observed age-disease interactions occur across these diseases caused by different aetiologies. It is plausible that old age increases the expansion of blood cells with somatic mutations (or clonal haematopoiesis)(23), leading to over-activation of immune cells such as neutrophils and macrophages to disease-causing pathogens or reactants(24), subsequently releasing more proteolytic enzymes to the circulation that digest elastin in the vasculature. As such, elevated cDES concentrations signal a harmful inflammatory effect to the cardiovascular system. On the other hand, age associated decline of renal function might also influence the elimination of cDES and cDES containing peptides from the circulation leading to higher cDES concentrations, although our current evidence did not show consistency. In our two previous studies where renal function data are available, we found an association between renal function and cDES concentrations in acute myocardial infarction(16) but not in COPD(15). The reason for this discrepancy is unclear but it is possible that the disease population or patient conditions (e.g., acute vs stable condition) could affect the relationship.

Few proven interventions are available that prevent or minimise elastin degradation in humans. To date, alpha-1 antitrypsin augmentation is the only treatment showing the ability of reducing circulating desmosine levels in a randomised trial although the magnitude of treatment effect was small(25) and it is currently only relevant to alpha-1 antitrypsin deficiency, a rare genetic condition that is associated with emphysema. Next generation systematic anti-proteinase therapy such as DPP1 inhibitors may offer promise especially for bronchiectasis.(26) It would be of great interest to test whether anti-aging therapies such as calorie restriction and caloric restriction mimetics (e.g. metformin) could impact elastin degradation in age-related diseases in human. A recent animal study showing that calorie restriction was

able to reduce arterial aging by reducing proinflammation associated elastin degradation supports this concept.(27)

We acknowledge several limitations in this study. First, we were not able to estimate the contribution of renal function to the observed age-disease interaction due to the lack of data availability. Second, the comorbidity data were not always available and therefore the influence of the comorbidity cannot be always excluded. Third, we did not include the acute myocardial infarction study(16) in the current study as the data were not available.

In summary, we conclude that accelerated elastin degradation by age-disease interaction is a common feature in age-related diseases.

Declarations

Acknowledgements

The authors received no financial support for this study. The dataset is available from the corresponding author on reasonable request.

Author contributions

AMC, CCL, BEM, RTS, CEB, NCT, JDC, MJB, DN, FK and JTJH contributed to the study design and data collection. NS and JTJH carried out data analysis and wrote the first draft. All authors contributed to revising the manuscript for important content and approval of final version.

References

1. Chang AY, Skirbekk VF, Tyrovolas S, Kassebaum NJ, Dieleman JL. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. *Lancet Public Health*. 2019;4(3):e159-e67.
2. Harris RE. *Epidemiology of chronic disease: global perspectives*: Jones & Bartlett Learning; 2019.
3. MacNee W, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. *Eur Respir J*. 2014;44(5):1332-52.
4. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell*. 2013;153(6):1194-217.
5. Toyama BH, Hetzer MW. Protein homeostasis: live long, won't prosper. *Nat Rev Mol Cell Biol*. 2013;14(1):55-61.
6. Heinz A. Elastic fibers during aging and disease. *Ageing Res Rev*. 2021;66:101255.
7. Shapiro SD, Endicott SK, Province MA, Pierce JA, Campbell EJ. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. *J Clin Invest*. 1991;87(5):1828-34.

8. Chen W, Smeekens JM, Wu R. Systematic study of the dynamics and half-lives of newly synthesized proteins in human cells. *Chem Sci*. 2016;7(2):1393-400.
9. Cocciolone AJ, Hawes JZ, Staiculescu MC, Johnson EO, Murshed M, Wagenseil JE. Elastin, arterial mechanics, and cardiovascular disease. *Am J Physiol Heart Circ Physiol*. 2018;315(2):H189-H205.
10. Maurice P, Blaise S, Gayral S, Debelle L, Laffargue M, Hornebeck W, et al. Elastin fragmentation and atherosclerosis progression: the elastokine concept. *Trends Cardiovasc Med*. 2013;23(6):211-21.
11. Huang JT, Bolton CE, Miller BE, Tal-Singer R, Rabinovich RA, Palmer CN, et al. Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. *Eur Respir J*. 2016;48(4):1215-8.
12. Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, et al. Neutrophil Elastase Activity is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. *Am J Respir Crit Care Med*. 2017;195(10):1384-93.
13. Mordi IR, Forsythe RO, Gellatly C, Iskandar Z, McBride OM, Saratzis A, et al. Plasma Desmosine and Abdominal Aortic Aneurysm Disease. *J Am Heart Assoc*. 2019;8(20):e013743.
14. Huang JT, Kuzmanova E, Dicker AJ, Keir HR, Finch S, Aliberti S, et al. Serum Desmosine is Associated with Long-term All-cause and Cardiovascular Mortality in Bronchiectasis. *Am J Respir Crit Care Med*. 2020;202(6):897-9.
15. Rabinovich RA, Miller BE, Wrobel K, Ranjit K, Williams MC, Drost E, et al. Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. *Eur Respir J*. 2016;47(5):1365-73.
16. Ali K, Israr MZ, Ng LL, Mordi I, Lang CC, Kuzmanova E, et al. Plasma desmosine for prediction of outcomes after acute myocardial infarction. *Front Cardiovasc Med*. 2022;9:992388.
17. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). *Eur Respir J*. 2008;31(4):869-73.
18. Huang JT, Chaudhuri R, Albarbarawi O, Barton A, Grierson C, Rauchhaus P, et al. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. *Thorax*. 2012;67(6):502-8.
19. Investigators MRS. Aortic Wall Inflammation Predicts Abdominal Aortic Aneurysm Expansion, Rupture, and Need for Surgical Repair. *Circulation*. 2017;136(9):787-97.
20. Vidailac C, Yong VFL, Jaggi TK, Soh MM, Chotirmall SH. Gender differences in bronchiectasis: a real issue? *Breathe (Sheff)*. 2018;14(2):108-21.
21. van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets the eye. *BMC Med*. 2009;7:12.
22. Albarbarawi O, Barton A, Miller D, McSharry C, Chaudhuri R, Thomson NC, et al. Characterization and validation of an isotope-dilution LC-MS/MS method for quantification of total desmosine and isodesmosine in plasma and serum. *Bioanalysis*. 2013;5(16):1991-2001.

23. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371(26):2488-98.
24. Cook EK, Luo M, Rauh MJ. Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity. *Exp Hematol*. 2020;83:85-94.
25. Ma S, Lin YY, Cantor JO, Chapman KR, Sandhaus RA, Fries M, et al. The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. *Chronic Obstr Pulm Dis*. 2016;4(1):34-44.
26. Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, et al. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. *N Engl J Med*. 2020;383(22):2127-37.
27. Wang M, Zhang L, Zhu W, Zhang J, Kim SH, Wang Y, et al. Calorie Restriction Curbs Proinflammation That Accompanies Arterial Aging, Preserving a Youthful Phenotype. *J Am Heart Assoc*. 2018;7(18):e009112.

Figures




Figure 1

Age-dependent elastin degradation was accelerated in COPD, AAA, bronchiectasis, and rheumatoid arthritis. A-E: Scatterplots of cDES against age in control subjects without inflammatory diseases (A), bronchiectasis (B), RA (C), COPD (D), AAA (E).

F: Predicted linear mixed model of log transformed cDES levels and age (≥ 65 years) in bronchiectasis and the control group ($p=0.02$ for the age and disease interaction). Note $\log_{10}(\text{cDES})$ was used to ensure normality assumption for residuals. G: Predicted linear mixed model of cDES levels and age (≥ 65 years) in RA and the control group ($p=0.003$ for the age and disease interaction). H: Predicted linear mixed model of cDES levels and age in AAA ($p<0.001$, for the age and disease interaction). I: Predicted linear mixed model of cDES levels in COPD with ($n=507$) or without CVDs ($n=472$) ($p=0.037$, for the age and disease interaction) in the ECLIPSE cohort. Solid regression lines are labelled with equations. Dashed lines represent 95% confidence intervals.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryTables.docx](#)